首页 | 本学科首页   官方微博 | 高级检索  
检索        

普萘洛尔联合5-单硝酸异山梨酯对肝硬化患者门静脉血流量影响的研究
引用本文:胡良凯,张建民,孙晓岚,张英虎,陈薇敏.普萘洛尔联合5-单硝酸异山梨酯对肝硬化患者门静脉血流量影响的研究[J].实用诊断与治疗杂志,2009,23(2).
作者姓名:胡良凯  张建民  孙晓岚  张英虎  陈薇敏
作者单位:上海市杨浦区市东医院消化内科,上海市,200438
摘    要:目的:观察普萘洛尔联合5-单硝酸异山梨酯对肝硬化患者门静脉血流的影响。方法:42例肝硬化门静脉高压患者,随机分为普萘洛尔组14例,5-单硝酸异山梨酯组14例,普萘洛尔与5-单硝酸异山梨酯联合组14例。分别给上述3组普萘洛尔10 mg/次,3次/d,口服;5-单硝酸异山梨酯40 mg/次,1次/d,口服;普萘洛尔10 mg/次,3次/d,5-单硝酸异山梨酯40 mg/次,1次/d,口服;疗程均为12周。于治疗前后观察门静脉系统血流动力学参数。结果:普萘洛尔组,联合组2组治疗前后门静脉血流量,脾静脉血流量均显著下降(P<0.05),5-单硝酸异山梨酯组门静脉血流量,脾静脉血流量治疗前后差异无统计学意义(P>0.05)。联合组门静脉血流量,脾静脉血流量下降幅度优于普萘洛尔组(P<0.05)。结论:普萘洛尔联合5-单硝酸异山梨酯更有效降低门静脉血流量,具有预防上消化道出血的作用。

关 键 词:肝硬化  普萘洛尔  5-单硝酸异山梨酯  门静脉高压  

Study on propranolol plus isosorbid-5-mononitrate for portal hypertension in patients with hepatic cirrhosis
HU Liangkai,ZHANG Jianmin,SUN Xiaolan,ZHANG Yinghu,CHEN Weimin.Study on propranolol plus isosorbid-5-mononitrate for portal hypertension in patients with hepatic cirrhosis[J].Journal of Practical Diagnosis and Therapy,2009,23(2).
Authors:HU Liangkai  ZHANG Jianmin  SUN Xiaolan  ZHANG Yinghu  CHEN Weimin
Abstract:Objective To observe the therapeutic effect of isosorbid-5-mononitrate plus propranolol on portal hypertension in patients with hepatic cirrhosis.Methods Fourty-two patients with hepatic cirrhosis were divided into three groups: propranolol therapy group,isosorbid-5-mononitrate therapy group,two drugs combination therapy group,14 cases in each group.The patients in propranolol therapy group were given propranolol 10 mg,three times a day.The isosorbid-5-mononitrate therapy group was given isosorbid-5-mononit...
Keywords:Hepatic cirrhosis  propranolol  isosorbid-5-mononitrate  portal hypertension  
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号